---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-007911"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:56:09.145248+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx preliminary Q4 revenue ~$20.3M record; guides 2022 revenue $80-85M

## Summary
- Preliminary Q4 2021 revenue ~$20.3M (record); full-year revenue rose 42% YoY.
- GAAP net income $0.6M; record quarterly adjusted EBITDA $4.0M.
- 2022 guidance: revenue $80-85M (31-39% growth); gross margins 57-60%.
- New KPIs: avg revenue per top-20 pharma manufacturer $2.5M; net revenue retention 127%; revenue per FTE $730K.
- Top 20 pharma customer penetration increased to 95% from 85% YoY.

## SEC filing metadata
- accession: 0001213900-22-007911
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022007911/0001213900-22-007911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022007911/ea155745-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-007911
- JSON: https://secwatch.observer/filing/0001213900-22-007911.json
- Plain text: https://secwatch.observer/filing/0001213900-22-007911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.